Rituximab use in interstitial pneumonia with autoimmune features shows similar outcomes to control group
Rituximab shows similar outcomes for IPAF patients in small study
This retrospective case-control study of 14 rituximab-treated and 19 control patients with interstitial pneumonia with autoimmune features f…
A small study found that patients with a rare lung condition had similar outcomes whether they received rituximab or not, suggesting limited…
Rituximab Shows Long-Term Remission in Pediatric Steroid-Dependent Nephrotic Syndrome
Rituximab Helps Kids With Kidney Swelling
This retrospective cohort study of 42 children with steroid-dependent or frequently relapsing nephrotic syndrome found that rituximab led to…
Imagine a child who needs medicine just to stay dry.
Obinutuzumab-guided regimen achieves high remission in refractory membranous nephropathy patients
New Dosing Strategy Helps Kidney Disease Patients Who Didn’t Respond to Standard Treatment
This single-center retrospective cohort study evaluated 33 patients with refractory membranous nephropathy treated with a B-cell reconstitut…
For patients with a stubborn kidney disease who ran out of options, a smarter dosing strategy may offer a new path to recovery.
Retrospective review of tocilizumab, rituximab, and azathioprine in chronic relapsing inflammatory optic neuropathy
New Clue Found in Stubborn Eye Inflammation
This retrospective analysis reviews tocilizumab, rituximab, and azathioprine use in 60 patients with chronic relapsing inflammatory optic ne…
Knowing a patient's blood marker status can guide doctors to the right therapy to stop recurring eye inflammation.
Systematic review of immunosuppression for SLE-associated intestinal pseudo-obstruction
SLE Can Shut Down the Gut — But It Might Be Reversible
This review synthesized 43 cases of SLE-associated intestinal pseudo-obstruction.
Lupus can paralyze the gut without a blockage, but early treatment with immunosuppressives often reverses this dangerous complication.
Scoping review synthesizes immunosuppressive strategies and outcomes in solid organ transplantation
New Drug Strategies Aim to Stop Your Body From Rejecting a Transplant
This scoping review examines immunosuppressive strategies for solid organ transplant patients, including conventional, biologic, and emergin…
New drug strategies aim to stop your body from attacking a new organ, protecting transplants longer while reducing dangerous side effects fr…
Switching therapy after rituximab resistance in AQP4-IgG+ NMOSD shows variable relapse outcomes
New Hope for Tough-to-Treat Nerve Disorder
This single-center, retrospective case series of 10 adults with AQP4-IgG+ NMOSD who were resistant to rituximab evaluated switching therapy.
Patients with a rare nerve disease who stopped responding to standard treatment found relief after switching to new therapies that prevented…
Rituximab pharmacokinetics vary widely in membranous nephropathy, minimal change disease, and lupus nephritis patients
Rituximab Works — But Only If Your Body Keeps Enough of It
This review examined pharmacokinetic profiling of rituximab in patients with glomerular diseases.
Rituximab helps kidney disease patients only if their bodies keep enough of it in the blood, since some people clear the drug too fast and g…
Phase 1b trial of intravenous B001 shows favorable safety in aquaporin-4-positive NMOSD patients
A New MS-Like Disease Drug Passes Its First Human Safety Test
This Phase 1b randomized, double-blind, placebo-controlled trial evaluated intravenous B001 in 22 patients with aquaporin-4 immunoglobulin G…
A new drug for a rare nerve disease that can cause blindness and paralysis passed its first human safety test with no severe side effects se…
Meta-analysis of novel therapies for follicular lymphoma progression within 24 months shows high response rates
New treatments show high response rates for advanced follicular lymphoma patients
This systematic review and meta-analysis evaluated outcomes for patients with follicular lymphoma experiencing disease progression within 24…
New powerful medicines help 91% of advanced follicular lymphoma patients whose disease returned quickly after treatment.
BR regimen shows survival outcomes in newly diagnosed Waldenstroms Macroglobulinemia patients
A Rare Blood Cancer With an 8-Year Survival: What Real-World Data Shows
This single-center retrospective analysis evaluated 89 newly diagnosed Waldenstroms Macroglobulinemia patients treated with the BR regimen.
New real-world data shows patients with the rare blood cancer Waldenstrom's macroglobulinemia live a median of over 8 years after diagnosis.
Narrative review outlines clinical framework for managing primary Sjögren's disease with interstitial lung disease
New Hope for Sjögren's Patients with Lung Scarring
A narrative review synthesizes evidence on managing primary Sjögren's disease with interstitial lung disease, highlighting a pragmatic clini…
Lung scarring in Sjögren's disease can be deadly, but new strategies targeting specific disease patterns offer a path forward for patients.